Nov 30, 2022 / 06:00PM GMT
Allison Marie Bratzel - Piper Sandler & Co., Research Division - Research Analyst
Okay. I think we can go ahead and get started. My name is Ally Bratzel. I'm a biotech analyst here at Piper Sandler. It's my pleasure to introduce our next company, argenx. Joining us today, we have Karl Gubitz, Chief Financial Officer; and Keith Woods, Chief Operating Officer.
So thanks for joining us. This is going to be a fireside chat format. But before we jump into Q&A, just to level set for investors, Karl, could you just give a quick overview of argenx? The story and the setup into 2023?
Karl Gubitz - argenx SE - CFO
Thank you very much, Ally. Good afternoon, everybody. Yes, 2022 has been a very busy and successful year for us. We've proved that we can add value across the value chain, not only both first-in-class, best-in-class drugs, design innovative trials, [getting] through the discovery and development programs and then launch.
We've launched in the U.S., Japan and in Europe and Germany in 2022. For a company of our size to launch in 3
argenx SE at Piper Sandler Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers